Table 1.
Clinical and tumor characteristics for breast cancer patients
| Characteristic | All patients (n = 131) | |
|---|---|---|
| n | % | |
| Age(years) | ||
| Mean | 62.6 | |
| SD | 10.7 | |
| ≤60 | 57 | 43.51 |
| >60 | 74 | 56.49 |
| Sex | ||
| Male | 0 | 0 |
| Female | 131 | 100 |
| Histology | ||
| Ductal | 131 | 100 |
| Tumor grade | ||
| Well or moderately differentiated | 63 | 48.09 |
| Poorly differentiated | 68 | 51.91 |
| ER/PR status | ||
| Positive | 77 | 58.78 |
| Negetaive | 54 | 41.22 |
| HER‐2 status | ||
| Positive | 53 | 40.46 |
| Negetaive | 78 | 59.54 |
| Ki‐67 score | ||
| <14% | 20 | 15.27 |
| ≥14% | 111 | 84.73 |
| Chemotherapy | ||
| Anthracycline | 43 | 32.82 |
| Taxane | 33 | 25.19 |
| Anthracycline/t axane | 55 | 41.98 |
| Outcome of chemotherapya | ||
| CR | 0 | 0.00 |
| PR | 69 | 52.67 |
| SD | 22 | 16.79 |
| PD | 40 | 30.53 |
a
Outcome of 2 cycles of first‐line chemotherapy in 131 breast cancer patients was classified according to the Response Evaluation Criteria in Solid Tumours 1.1 (RECIST 1.1) categories (complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD)). ER, estradiol receptor; PR, progesterone receptor; HER‐2, human epidermal growth factor receptor‐2.